Volume 21, Number 1Review ArticlesImmunotherapy in Urological TumorsTreatment ReviewNikhil VasdevAnand SharmaNarin SuleymanOliver JonesThe past decade has seen significant improvement in our understanding of tumor biological features, which has led to use of anti-programmed-death 1 (PD-1) and anti-PD ligand-1 (PD-L1) agents and cytotoxic T lymphocytes antigen 4 (CTLA-4) inhibitors in a multitude of cancers. These immunotherapeutic agents have shown activity in melanoma, lung, head and neck, colorectal, urological, and other cancers. This article details the use of immunotherapy agents in urothelial, renal, prostate, and testicular tumors. [Rev Urol. 2019;21(1):15–20] © 2019 MedReviews®, LLCImmunotherapyCytokinesurological tumorsimmune checkpoint inhibitorsrecombinant BCGcell wall-derived therapies